Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans

Like native DOPA, [18F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [18F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by h...

Full description

Saved in:
Bibliographic Details
Published inJournal of cerebral blood flow and metabolism Vol. 13; no. 4; pp. 668 - 675
Main Authors Cumming, Paul, Léger, Gabriel C., Kuwabara, Hiroto, Gjedde, Albert
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.07.1993
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Like native DOPA, [18F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [18F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by high-performance liquid chromatography (HPLC). In addition to the principal metabolite O-methyl-[18F]FDOPA (OMe-[18F]FDOPA), two decarboxylated metabolites were detected in plasma from carbidopa pretreated subjects. The concentrations of each metabolite during 90 min following tracer injection could be described as a function of the concentration of [18F]FDOPA, and two rate constants; k0, the rate of formation, and k–1, the rate of clearance. Plasma metabolite time series generated from total plasma activity curves and measured rate constants were in close agreement with the actual concentrations determined by HPLC fractionation. Population means for k0 (0.011 ± 0.002 min−1) and k–1, (0.010 ± 0.003 min−1) were used to generate “simulated” plasma curves. The measured and generated plasma curves were used as inputs for estimation of partition and decarboxylation coefficients of [18F]FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high variability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC measurements.
AbstractList Like native DOPA, [ 18 F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([ 18 F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [ 18 F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by high-performance liquid chromatography (HPLC). In addition to the principal metabolite O-methyl-[ 18 F]FDOPA (OMe-[ 18 F]FDOPA), two decarboxylated metabolites were detected in plasma from carbidopa pretreated subjects. The concentrations of each metabolite during 90 min following tracer injection could be described as a function of the concentration of [ 18 F]FDOPA, and two rate constants; k 0 , the rate of formation, and k –1 , the rate of clearance. Plasma metabolite time series generated from total plasma activity curves and measured rate constants were in close agreement with the actual concentrations determined by HPLC fractionation. Population means for k 0 (0.011 ± 0.002 min −1 ) and k –1 , (0.010 ± 0.003 min −1 ) were used to generate “simulated” plasma curves. The measured and generated plasma curves were used as inputs for estimation of partition and decarboxylation coefficients of [ 18 F]FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high variability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC measurements.
Like native DOPA, [18F]-6-fluoro-L-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [18F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by high-performance liquid chromatography (HPLC). In addition to the principal metabolite O-methyl-[18F]FDOPA (OMe[18F]FDOPA), two decarboxylated metabolites were detected in plasma from carbidopa pretreated subjects. The concentrations of each metabolite during 90 min following tracer injection could be described as a function of the concentration of [18F]FDOPA, and two rate constants; k0, the rate of formation, and k-1, the rate of clearance. Plasma metabolite time series generated from total plasma activity curves and measured rate constants were in close agreement with the actual concentrations determined by HPLC fractionation. Population means for k0 (0.011 +/- 0.002 min-1) and k-1 (0.010 +/- 0.003 min-1) were used to generate "simulated" plasma curves. The measured and generated plasma curves were used as inputs for estimation of partition and decarboxylation coefficients of [18F]FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high variability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC measurements.
Like native DOPA, [18F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [18F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by high-performance liquid chromatography (HPLC). In addition to the principal metabolite O-methyl-[18F]FDOPA (OMe-[18F]FDOPA), two decarboxylated metabolites were detected in plasma from carbidopa pretreated subjects. The concentrations of each metabolite during 90 min following tracer injection could be described as a function of the concentration of [18F]FDOPA, and two rate constants; k0, the rate of formation, and k–1, the rate of clearance. Plasma metabolite time series generated from total plasma activity curves and measured rate constants were in close agreement with the actual concentrations determined by HPLC fractionation. Population means for k0 (0.011 ± 0.002 min−1) and k–1, (0.010 ± 0.003 min−1) were used to generate “simulated” plasma curves. The measured and generated plasma curves were used as inputs for estimation of partition and decarboxylation coefficients of [18F]FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high variability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC measurements.
Author Gjedde, Albert
Léger, Gabriel C.
Kuwabara, Hiroto
Cumming, Paul
Author_xml – sequence: 1
  givenname: Paul
  surname: Cumming
  fullname: Cumming, Paul
  organization: Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada
– sequence: 2
  givenname: Gabriel C.
  surname: Léger
  fullname: Léger, Gabriel C.
  organization: Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada
– sequence: 3
  givenname: Hiroto
  surname: Kuwabara
  fullname: Kuwabara, Hiroto
  organization: Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada
– sequence: 4
  givenname: Albert
  surname: Gjedde
  fullname: Gjedde, Albert
  organization: Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/8314919$$D View this record in MEDLINE/PubMed
BookMark eNp1kM9PwjAYhhuDQUCPHk12MmostnT9dSQgYkICB01M1DTt1slwW7Flifz3DiHePH2H9_nefN_TBa3KVRaAc4z6GBFxt0pMVvaxlKQv6BHoYEol5AizFuigAceQcfFyArohrBBCglDaBm1BcCyx7IC3xVL7UifuM6_sJk9C5LJoUehQ6ojBVywm75Oidt7BApLbGI7z5Tb17nu7XtpqW-hCV81idLUnx_PF8DrKq2hal7oKp-A400WwZ4fZA8-T-6fRFM7mD4-j4Qwm8UBsoKSYsYxSRLjVTGidEC4FjSk1zGKKUmMQi42JjU4MoZbHsUiR5cYSk2qGSA9c7nvX3n3VNmxUmYfEFs1x1tVBccqlpINBA8I9mHgXgreZWvu81H6rMFI7m-rXptrZVII2_MWhuDalTf_og74mv9nnQX9YtXK1r5o__yn7AbfNfwQ
CitedBy_id crossref_primary_10_1016_0006_2952_95_00216_M
crossref_primary_10_1002_syn_10034
crossref_primary_10_1007_s11682_021_00509_5
crossref_primary_10_1016_j_neuroimage_2007_12_045
crossref_primary_10_1016_0024_3205_95_00147_X
crossref_primary_10_1177_0271678X15610585
crossref_primary_10_1111_j_1600_0404_2004_00299_x
crossref_primary_10_1002_syn_22029
crossref_primary_10_1038_s41380_018_0042_4
crossref_primary_10_1523_JNEUROSCI_0805_07_2007
crossref_primary_10_1111_j_1749_6632_1997_tb48637_x
crossref_primary_10_1016_j_biopsych_2018_07_003
crossref_primary_10_1016_j_neurobiolaging_2008_05_005
crossref_primary_10_1371_journal_pone_0073903
crossref_primary_10_1523_JNEUROSCI_1560_14_2014
crossref_primary_10_1016_j_pscychresns_2019_07_005
crossref_primary_10_1038_npp_2014_87
crossref_primary_10_1038_s41380_021_01108_y
crossref_primary_10_2217_npy_11_51
crossref_primary_10_1016_j_neuroimage_2009_11_035
crossref_primary_10_1038_s41598_017_16020_1
crossref_primary_10_1111_j_1471_4159_1993_tb13651_x
crossref_primary_10_3390_ijms22041645
crossref_primary_10_1016_S0165_0270_01_00453_8
crossref_primary_10_3727_000000002783985314
crossref_primary_10_1038_sj_npp_1300103
crossref_primary_10_1093_brain_awz093
crossref_primary_10_1038_s41380_019_0570_6
crossref_primary_10_1097_00004647_199711000_00014
crossref_primary_10_1001_jamapsychiatry_2017_2943
crossref_primary_10_1002__SICI_1098_2396_199712_27_4_336__AID_SYN7_3_0_CO_2_D
crossref_primary_10_1016_j_biopsych_2012_11_017
crossref_primary_10_1034_j_1600_0404_2001_103005309_x
crossref_primary_10_1007_s00213_014_3523_4
crossref_primary_10_1016_j_nucmedbio_2020_01_001
crossref_primary_10_1038_jcbfm_2013_29
crossref_primary_10_1002_hbm_20325
crossref_primary_10_1093_schbul_sbaa128
crossref_primary_10_1038_sj_jcbfm_9600202
crossref_primary_10_7554_eLife_29088
crossref_primary_10_2967_jnumed_114_145565
crossref_primary_10_1002__SICI_1098_2396_199812_30_4_351__AID_SYN2_3_0_CO_2_2
crossref_primary_10_1016_S0969_8051_00_00187_6
crossref_primary_10_1016_S0014_2999_97_01157_6
crossref_primary_10_1016_j_neuroimage_2005_11_014
crossref_primary_10_1002__SICI_1098_2396_19990915_33_4_247__AID_SYN1_3_0_CO_2_6
crossref_primary_10_1016_S0006_8993_97_00552_0
crossref_primary_10_1186_s13550_023_01049_3
crossref_primary_10_1523_JNEUROSCI_1398_13_2013
crossref_primary_10_1002__SICI_1098_2396_199805_29_1_37__AID_SYN4_3_0_CO_2_C
crossref_primary_10_1038_tp_2016_270
crossref_primary_10_1016_S0736_5748_98_00017_3
crossref_primary_10_1038_sj_jcbfm_9600079
crossref_primary_10_1017_S0033291716002051
crossref_primary_10_1016_j_neuroimage_2009_12_058
crossref_primary_10_1016_S0165_0270_97_00094_0
crossref_primary_10_1177_096368970000900210
crossref_primary_10_1177_02698811221122031
crossref_primary_10_1002_1098_2396_200008_37_2_81__AID_SYN1_3_0_CO_2
crossref_primary_10_1016_0969_8051_95_02083_7
crossref_primary_10_1002_syn_1077
crossref_primary_10_1016_j_biopsych_2013_05_027
crossref_primary_10_1038_s41386_020_0740_x
crossref_primary_10_1002_syn_1071
crossref_primary_10_1016_j_cpet_2013_08_003
crossref_primary_10_1177_1073858409338217
crossref_primary_10_1097_00004647_199910000_00011
crossref_primary_10_1038_s41386_020_00866_7
Cites_doi 10.1073/pnas.88.7.2721
10.1016/0006-2952(72)90392-9
10.1016/0006-2952(87)90526-0
10.1212/WNL.42.1.199
10.1038/jcbfm.1993.7
10.1038/317246a0
10.1002/cpt1972134584
10.1038/252237a0
10.1159/000116170
10.1016/0006-8993(91)90037-V
10.1016/0006-2952(90)90601-G
10.1016/0024-3205(90)90228-J
10.1038/jcbfm.1990.124
10.1212/WNL.34.2.198
10.1016/0024-3205(86)90403-0
10.1212/WNL.40.1.156
10.1038/jcbfm.1991.129
10.1111/j.1471-4159.1987.tb04135.x
10.1038/jcbfm.1991.155
10.1038/305137a0
10.1212/WNL.17.5.427
10.1097/00002826-199012000-00006
10.1016/0006-2952(88)90725-3
ContentType Journal Article
Copyright 1993 International Society for Cerebral Blood Flow and Metabolism
Copyright_xml – notice: 1993 International Society for Cerebral Blood Flow and Metabolism
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1038/jcbfm.1993.85
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
EISSN 1559-7016
EndPage 675
ExternalDocumentID 10_1038_jcbfm_1993_85
8314919
10.1038_jcbfm.1993.85
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GroupedDBID ---
-Q-
-TM
.55
.GJ
0R~
29K
2WC
36B
39C
3O-
3V.
4.4
53G
54M
5GY
5RE
5VS
70F
7X7
88A
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AABMB
AACKU
AACMV
AADUE
AAEWN
AAGGD
AAGMC
AAJIQ
AAJPV
AAKGS
AAMGE
AANSI
AAPEO
AAQGT
AAQXH
AARDL
AARIX
AATAA
AATBZ
AAUAS
AAVDI
AAXOT
AAYTG
AAZBJ
ABAWP
ABAWZ
ABCCA
ABDWY
ABEIX
ABFWQ
ABHKI
ABJNI
ABKRH
ABLUO
ABNCE
ABPGX
ABPNF
ABQKF
ABQNX
ABQXT
ABRHV
ABUWG
ABVFX
ABXGC
ABYTW
ACARO
ACDSZ
ACDXX
ACFEJ
ACFMA
ACGBL
ACGFO
ACGFS
ACGZU
ACJTF
ACLFY
ACLHI
ACNXM
ACOFE
ACOXC
ACPRK
ACROE
ACSIQ
ACTQU
ACUAV
ACUIR
ACXKE
ACXMB
ADBBV
ADEIA
ADMPF
ADRRZ
ADTBJ
ADUKL
ADZZY
AECGH
AENEX
AEPTA
AEQLS
AESZF
AEUHG
AEUIJ
AEWDL
AEWHI
AEXFG
AEXNY
AFEET
AFFNX
AFFZS
AFKRA
AFKRG
AFMOU
AFOSN
AFQAA
AFUIA
AGKLV
AGNHF
AGWFA
AHMBA
AIGRN
AIOMO
AJABX
AJEFB
AJMMQ
AJSCY
AJUZI
AJXAJ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALTZF
AMCVQ
ANDLU
AOIJS
ARTOV
AUTPY
AYAKG
B8M
BAWUL
BBNVY
BBRGL
BDDNI
BENPR
BHPHI
BKIIM
BKSCU
BPACV
BPHCQ
BSEHC
BVXVI
BWJAD
C45
CAG
CBRKF
CCPQU
CDWPY
CFDXU
COF
CORYS
CQQTX
CS3
CUTAK
D-I
DC-
DC.
DIK
DOPDO
DV7
E3Z
EBS
EE.
EJD
EMOBN
F5P
FHBDP
FYUFA
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
HCIFZ
HMCUK
HYE
HZ~
J8X
JCYGO
JSO
K.F
KQ8
LK8
M0L
M1P
M4V
M7P
O9-
OK1
OVD
P2P
P6G
PQQKQ
PROAC
PSQYO
Q1R
Q2X
RNS
RNTTT
ROL
RPM
SCNPE
SFC
SHG
SPQ
SPV
TEORI
TR2
UKHRP
W2D
X7M
YFH
YOC
ZGI
ZONMY
ZPPRI
ZRKOI
ZSSAH
ZXP
ACJER
AFVCE
AJXGE
ALKWR
CGR
CUY
CVF
ECM
EIF
H13
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c428t-95166f55037ea68aac37985455b6e150dbb064bb4bacb35e7448d0e7be3bda603
ISSN 0271-678X
IngestDate Fri Aug 16 10:28:05 EDT 2024
Wed Sep 11 13:45:53 EDT 2024
Tue Oct 15 23:16:12 EDT 2024
Tue Jul 16 20:52:30 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords O-Methyl-6-[18F]fluoro-l-DOPA
Metabolism
Positron emission tomography
Modeling
6-[18F]Fluoro-l-DOPA
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c428t-95166f55037ea68aac37985455b6e150dbb064bb4bacb35e7448d0e7be3bda603
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://journals.sagepub.com/doi/pdf/10.1038/jcbfm.1993.85
PMID 8314919
PQID 75799522
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_75799522
crossref_primary_10_1038_jcbfm_1993_85
pubmed_primary_8314919
sage_journals_10_1038_jcbfm_1993_85
PublicationCentury 1900
PublicationDate 1993-07-01
PublicationDateYYYYMMDD 1993-07-01
PublicationDate_xml – month: 07
  year: 1993
  text: 1993-07-01
  day: 01
PublicationDecade 1990
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: United States
PublicationTitle Journal of cerebral blood flow and metabolism
PublicationTitleAlternate J Cereb Blood Flow Metab
PublicationYear 1993
Publisher SAGE Publications
Publisher_xml – name: SAGE Publications
References Garnett, Firnau, Nahmias 1983; 305
Da Prada, Kettler, Zrcher, Schnaffner, Haefely 1987; 27
Cedarbaum, Léger, Reches, Guttman 1990; 6
Cumming, Hausser, Martin, Grierson, Adam, Ruth, McGeer 1988; 37
Doudet, McLellan, Carson, Adams, Miyake, Aigner, Finn, Cohen 1991; 11
Kuwabara, Cumming, Reith, Léger, Diksic, Evans, Gjedde 1993; 13
Cumming, Boyes, Martin, Adam, Ruth, McGeer 1987a; 48
Boyes, Cumming, Martin, McGeer 1986; 39
Calne, Langsten, Martin, Stoessl, Ruth, Adam, Schulzer 1985; 317
Jenner, Rose 1974; 252
Reith, Dyve, Kuwabara, Guttman, Diksic, Gjedde 1990; 10
Hoehn, Yahr 1967; 17
Léger, Guttman, Leblanc, Cedarbaum, Gjedde, Reches 1990; 40
Melega, Hoffman, Luxen, Nissenson, Phelps, Barrio 1990b; 47
Guldberg, Marsden 1975; 27
Huang, Yu, Barrio, Grafton, Melega, Hoffman, Satyamurthy, Mazziotta, Phelps 1991; 11
Bianchine, Messiha, Hsu 1973; 13
Ward, Trombley, Calne, Kopin 1984; 34
Doller, Connor, Lock, Sloviter, Dvorchik, Vesell 1978; 6
Melega, Hoffman, Schneider, Phelps, Barrio 1991; 543
Goodall, Alton 1972; 21
Melega, Luxen, Perlmutter, Nissenson, Phelps, Barrio 1990a; 39
Laihinen, Rinne, Rinne, Haaparanta, Ruotsalainen, Bergman, Solin 1992; 42
Cumming, Boyes, Martin, Adam, Ruth, McGeer 1987b; 36
Gjedde, Reith, Dyve, Léger, Guttman, Diksic, Evans, Kuwabara 1991; 88
bibr22-jcbfm.1993.85
bibr6-jcbfm.1993.85
Guldberg HC (bibr14-jcbfm.1993.85) 1975; 27
bibr1-jcbfm.1993.85
bibr16-jcbfm.1993.85
bibr8-jcbfm.1993.85
bibr3-jcbfm.1993.85
Doller JH (bibr9-jcbfm.1993.85) 1978; 6
bibr11-jcbfm.1993.85
Léger GC (bibr20-jcbfm.1993.85) 1990; 40
bibr18-jcbfm.1993.85
bibr24-jcbfm.1993.85
bibr5-jcbfm.1993.85
bibr7-jcbfm.1993.85
bibr23-jcbfm.1993.85
bibr13-jcbfm.1993.85
bibr15-jcbfm.1993.85
bibr21-jcbfm.1993.85
bibr12-jcbfm.1993.85
bibr2-jcbfm.1993.85
bibr17-jcbfm.1993.85
bibr10-jcbfm.1993.85
bibr4-jcbfm.1993.85
bibr19-jcbfm.1993.85
bibr25-jcbfm.1993.85
References_xml – volume: 13
  start-page: 43
  year: 1993
  end-page: 56
  article-title: Human striatal l-DOPA decarboxylase activity estimated in vivo using 6-[ F]fluorodopa and positron emission tomography: Error analysis and application to normal subjects
  publication-title: J Cereb Blood Flow Metab
  contributor:
    fullname: Gjedde
– volume: 37
  start-page: 247
  year: 1988
  end-page: 250
  article-title: Kinetics of in vitro decarboxylation and the in vivo metabolism of 2- and 6- F-fluorodopa in the hooded rat
  publication-title: Biochem Pharmacol
  contributor:
    fullname: McGeer
– volume: 27
  start-page: 9
  year: 1987
  end-page: 20
  article-title: Inhibition of decarboxylase and levels of DOPA and 3- -methyldopa: A comparative study of benserazide versus carbidopa in rodents and of Madopar Standard versus Madopar HBS in volunteers
  publication-title: Eur Neurol
  contributor:
    fullname: Haefely
– volume: 40
  start-page: 156
  year: 1990
  article-title: Inhibition of 3- -methylfluorodopa formation with OR462: Attempts to simplify the fluorodopa model for PET analysis
  publication-title: Neurology
  contributor:
    fullname: Reches
– volume: 21
  start-page: 2,401
  year: 1972
  end-page: 2,408
  article-title: Metabolism of 3,4-dihydroxyphenylalanine (l-DOPA) in human subjects
  publication-title: Biochem Pharmacol
  contributor:
    fullname: Alton
– volume: 543
  start-page: 271
  year: 1991
  end-page: 276
  article-title: 6-[ F]Fluoro-l-DOPA metabolism in MPTP-treated monkeys: Assessment of tracer methodologies for positron emission tomography
  publication-title: Brain Res
  contributor:
    fullname: Barrio
– volume: 11
  start-page: 898
  year: 1991
  end-page: 913
  article-title: Kinetics and modeling of l-6-[ F]fluoro-DOPA in human positron emission tomographic studies
  publication-title: J Cereb Blood Flow Metab
  contributor:
    fullname: Phelps
– volume: 17
  start-page: 472
  year: 1967
  end-page: 542
  article-title: Parkinsonism: Onset, progression and mortality
  publication-title: Neurology
  contributor:
    fullname: Yahr
– volume: 305
  start-page: 137
  year: 1983
  end-page: 138
  article-title: Dopamine visualized in the basal ganglia of living man
  publication-title: Nature
  contributor:
    fullname: Nahmias
– volume: 317
  start-page: 246
  year: 1985
  end-page: 248
  article-title: Positron emission tomography after MPTP: Observations relating to the cause of Parkinson's disease
  publication-title: Nature
  contributor:
    fullname: Schulzer
– volume: 252
  start-page: 237
  year: 1974
  end-page: 238
  article-title: Dopamine 3- -sulfate, an end product of l-DOPA metabolism in Parkinson patients
  publication-title: Nature
  contributor:
    fullname: Rose
– volume: 13
  start-page: 584
  year: 1973
  end-page: 594
  article-title: Peripheral aromatic L-amino acid decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of l-2- C-DOPA
  publication-title: Clin Pharmacol Ther
  contributor:
    fullname: Hsu
– volume: 42
  start-page: 199
  year: 1992
  end-page: 203
  article-title: [ F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462)
  publication-title: Neurology
  contributor:
    fullname: Solin
– volume: 10
  start-page: 707
  year: 1990
  end-page: 719
  article-title: Blood-brain transfer and metabolism of 6-[ F]fluoro-l-dopa in rat
  publication-title: J Cereb Blood Flow Metab
  contributor:
    fullname: Gjedde
– volume: 39
  start-page: 1,853
  year: 1990a
  end-page: 1,860
  article-title: Comparative in vivo metabolism of 6-[ F]fluoro- -DOPA and [ H] -DOPA
  publication-title: Biochem Pharmacol
  contributor:
    fullname: Barrio
– volume: 34
  start-page: 198
  year: 1984
  end-page: 201
  article-title: l-DOPA decarboxylation in chronically treated patients
  publication-title: Neurology
  contributor:
    fullname: Kopin
– volume: 6
  start-page: 544
  year: 1990
  end-page: 552
  article-title: Effect of nitecapone (OR-462) on the pharmacokinetics of l-dopa and 3- -methyldopa formation in cynomolgus monkey
  publication-title: Clin Neuropharmacol
  contributor:
    fullname: Guttman
– volume: 47
  start-page: 149
  year: 1990b
  end-page: 157
  article-title: The effects of carbidopa on the metabolism of 6-[ F]fluoro-DOPA in rats, monkeys and humans
  publication-title: Life Sci
  contributor:
    fullname: Barrio
– volume: 6
  start-page: 164
  year: 1978
  end-page: 168
  article-title: Levodopa pharmacokinetics: Alterations after benserazide, a decarboxylase inhibitor
  publication-title: Drug Metab Dispos
  contributor:
    fullname: Vesell
– volume: 39
  start-page: 2,243
  year: 1986
  end-page: 2,252
  article-title: Determination of plasma [ F]-6-fluorodopa during positron emission tomography in carbidopa treated subjects
  publication-title: Life Sci
  contributor:
    fullname: McGeer
– volume: 48
  start-page: 601
  year: 1987a
  end-page: 608
  article-title: The metabolism of [ F]-6-fluoro-l-3,4-dihydroxyphenylalanine in the hooded rat
  publication-title: J Neurochem
  contributor:
    fullname: McGeer
– volume: 11
  start-page: 726
  year: 1991
  end-page: 734
  article-title: Distribution and kinetics of 3- -methyl-6-[ F]fluoro-l-DOPA in the rhesus monkey brain
  publication-title: J Cereb Blood Flow Metab
  contributor:
    fullname: Cohen
– volume: 27
  start-page: 135
  year: 1975
  end-page: 188
  article-title: Catechol- -methyltransferase: Pharmacological aspects and physiological role
  publication-title: Pharmacol Rev
  contributor:
    fullname: Marsden
– volume: 36
  start-page: 2,527
  year: 1987b
  end-page: 2,531
  article-title: Altered metabolism of [ F]-6-fluorodopa in the hooded rat following inhibition of catechol-) -methyltransferase with U-0521
  publication-title: Biochem Pharmacol
  contributor:
    fullname: McGeer
– volume: 88
  start-page: 2,721
  year: 1991
  end-page: 2,725
  article-title: Dopa decarboxylase activity of the living human brain
  publication-title: Proc Natl Acad Sci USA
  contributor:
    fullname: Kuwabara
– volume: 6
  start-page: 164
  year: 1978
  ident: bibr9-jcbfm.1993.85
  publication-title: Drug Metab Dispos
  contributor:
    fullname: Doller JH
– ident: bibr12-jcbfm.1993.85
  doi: 10.1073/pnas.88.7.2721
– ident: bibr13-jcbfm.1993.85
  doi: 10.1016/0006-2952(72)90392-9
– ident: bibr6-jcbfm.1993.85
  doi: 10.1016/0006-2952(87)90526-0
– volume: 27
  start-page: 135
  year: 1975
  ident: bibr14-jcbfm.1993.85
  publication-title: Pharmacol Rev
  contributor:
    fullname: Guldberg HC
– ident: bibr19-jcbfm.1993.85
  doi: 10.1212/WNL.42.1.199
– ident: bibr18-jcbfm.1993.85
  doi: 10.1038/jcbfm.1993.7
– ident: bibr3-jcbfm.1993.85
  doi: 10.1038/317246a0
– ident: bibr1-jcbfm.1993.85
  doi: 10.1002/cpt1972134584
– ident: bibr17-jcbfm.1993.85
  doi: 10.1038/252237a0
– ident: bibr8-jcbfm.1993.85
  doi: 10.1159/000116170
– ident: bibr23-jcbfm.1993.85
  doi: 10.1016/0006-8993(91)90037-V
– ident: bibr21-jcbfm.1993.85
  doi: 10.1016/0006-2952(90)90601-G
– ident: bibr22-jcbfm.1993.85
  doi: 10.1016/0024-3205(90)90228-J
– ident: bibr24-jcbfm.1993.85
  doi: 10.1038/jcbfm.1990.124
– ident: bibr25-jcbfm.1993.85
  doi: 10.1212/WNL.34.2.198
– ident: bibr2-jcbfm.1993.85
  doi: 10.1016/0024-3205(86)90403-0
– volume: 40
  start-page: 156
  year: 1990
  ident: bibr20-jcbfm.1993.85
  publication-title: Neurology
  doi: 10.1212/WNL.40.1.156
  contributor:
    fullname: Léger GC
– ident: bibr10-jcbfm.1993.85
  doi: 10.1038/jcbfm.1991.129
– ident: bibr5-jcbfm.1993.85
  doi: 10.1111/j.1471-4159.1987.tb04135.x
– ident: bibr16-jcbfm.1993.85
  doi: 10.1038/jcbfm.1991.155
– ident: bibr11-jcbfm.1993.85
  doi: 10.1038/305137a0
– ident: bibr15-jcbfm.1993.85
  doi: 10.1212/WNL.17.5.427
– ident: bibr4-jcbfm.1993.85
  doi: 10.1097/00002826-199012000-00006
– ident: bibr7-jcbfm.1993.85
  doi: 10.1016/0006-2952(88)90725-3
SSID ssj0008355
Score 1.7121232
Snippet Like native DOPA, [18F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation...
Like native DOPA, [18F]-6-fluoro-L-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation...
Like native DOPA, [ 18 F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([ 18 F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of...
SourceID proquest
crossref
pubmed
sage
SourceType Aggregation Database
Index Database
Publisher
StartPage 668
SubjectTerms Adult
Arteries
Carbidopa - pharmacology
Chromatography, High Pressure Liquid
Dihydroxyphenylalanine - analogs & derivatives
Dihydroxyphenylalanine - blood
Fluorine Radioisotopes
Humans
Parkinson Disease - blood
Reference Values
Tomography, Emission-Computed
Title Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans
URI https://journals.sagepub.com/doi/full/10.1038/jcbfm.1993.85
https://www.ncbi.nlm.nih.gov/pubmed/8314919
https://search.proquest.com/docview/75799522
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKEGIvCDYmyjUSbAINjySOnfRxDNqJm3jYpEoMRXbsQEeTTG0qVH49x5e0DVsl4CWq0sauzvfVPcf-zjkIPaM-50EUSNwLc6F3q3zMY59iRjMiaR4QZRJpP35ix6fRuyEddjqz1eySWhxkv67MK_kfVOEe4KqzZP8B2cWgcANeA75wBYTh-lcYf3Z1p3-Aq2jKLVemLfS04PsM79LXQdLfpW_y8ayaVPgDJmDPCMvR97nU4hWt7pqPtbTReZqLJ_oSQmm9XzAqbRO_6RofNlMTffA8tvr3_XxcWYFxoWog17gpT2gk2EXh2qcs-yXbU_pvljWD5Ybt-9lPrTTgreSJwbmScmX7VbrcPbKQtTYrWhgHGP4dh63ll6zQLFpZS5ntt3NpjbcV3c8zkRc615Ic2J4_K3hfFAbwhED45xbkdk1t9841dD2Me1QrQQfDpTIInFKjfG2-rSvNCvO-as26iW64gdpOzaVIpaUSNI7LyW10y6HlHVr63EEdVW6h7cOS11Ux9_Y8owE2hytb6OZR0_9vG539yS6vyj3LLo_hL8CUr0tmvVzHK--5-aRh1AtvVHqWT3fRaf_tydExdr04cAYBao3BEWcsh3CWxIqzhPOMxL0E3G8qmIKgQgoBzq0QkeCZIFTFEPZLX8VCESE588kO2iirUt1DHriEVCkS-Ur1ol4uBOEZi0MVcAgFgox00V5jzPTCllxJjVSCJKmxf6rtnya0i540pk7BNvqki5eqmk3TmOo6h2HYRTsWgcVADrAueqoRSd2PeXr1BPfXPf4AbS75_RBt1JOZegTOaS0eGyr9BhZfiDs
link.rule.ids 315,786,790,27955,27956
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+plasma+6-%5B18F%5Dfluoro-L-3%2C4-dihydroxyphenylalanine+%28%5B18F%5DFdopa%29+in+humans&rft.jtitle=Journal+of+cerebral+blood+flow+and+metabolism&rft.au=Cumming%2C+P&rft.au=L%C3%A9ger%2C+G+C&rft.au=Kuwabara%2C+H&rft.au=Gjedde%2C+A&rft.date=1993-07-01&rft.issn=0271-678X&rft.volume=13&rft.issue=4&rft.spage=668&rft_id=info:doi/10.1038%2Fjcbfm.1993.85&rft_id=info%3Apmid%2F8314919&rft.externalDocID=8314919
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0271-678X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0271-678X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0271-678X&client=summon